Application of Phochinenin I in preparation of medicine for preventing inflammation-induced diseases

Through the pathway of Phochinenin I inhibiting STAT3 and iNOS, the problem of lack of drugs used in the prior art to prevent inflammation-induced disease is solved, and effective regulation of inflammatory factors and cellular responses is achieved, and the potential for treating lung inflammation and other related diseases is achieved. .

CN119055622APending Publication Date: 2024-12-03THE SECOND HOSPITAL OF SHANDONG UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411176211.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-26
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

The prior art lacks the use of Phochinenin I for the preparation of drugs for preventing inflammation-induced diseases, especially in the treatment of pulmonary inflammation, chronic obstructive pulmonary disease, autoimmune disease, atherosclerotic disease and tumor diseases.

Method used

Phochinenin I reduces the production of inflammatory factors IL-6 and TNF-α and reduces NO secretion by inhibiting the phosphorylation of STAT3 and the production of iNOS, thereby regulating the cellular inflammatory response, and has the potential to develop as a target pathway to inhibit inflammation.

Benefits of technology

Phochinenin I showed significant anti-inflammatory activity, with the potential to be a leading drug for the treatment of inflammation, and was able to effectively prevent and treat the above diseases, especially in lung inflammation and chronic obstructive pulmonary diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119055622A_ABST
    Figure CN119055622A_ABST
Patent Text Reader

Abstract

The invention discloses an application of Phochinenin I in preparation of a medicine for preventing inflammation-induced diseases. The application is characterized in that the chemical structure of the Phochinenin I is as follows: # imgabs0 # Phochinenin I can be used for inhibiting inflammatory factors TNF-alpha and IL-6; the compound provided by the invention can be used for reducing intracellular ROS, regulating phosphorylation of STAT3, reducing expression of iNOS, inhibiting release of NO and increasing expression of Nrf-2, is an effective compound for treating inflammatory reaction related diseases, and provides a lead compound or a candidate drug for research and development of innovative drugs for treating inflammatory reaction related diseases. The invention relates to the technical field of medicines, relates to application of phenanthrene-bibenzyl dimer, and particularly relates to application of Phochinenin I in preparation of medicines for preventing inflammation-induced diseases. The technical problem to be solved by the invention is to provide application of Phochinenin I in preparation of drugs for preventing inflammation-induced diseases, and the Phochinenin I has the potential of becoming a leading drug for treating inflammation and is expected to be applied to preparation of drugs for preventing and treating lung inflammatory diseases, chronic obstructive pulmonary diseases, autoimmune diseases, atherosclerotic diseases or tumor diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the field of medical technology, and relates to the application of phenanthrene-bibenzyl dimer, and in particular to the application of phenanthrene-bibenzyl dimer in the preparation of drugs for preventing inflammation-induced diseases. Background Art

[0002] In recent years, with the increasing environmental pollution, drug abuse, aging population and other factors, human health has been greatly threatened. In particular, the new coronavirus (2019-nCoV) can cause a serious "cytokine storm", and excessive inflammatory factors can induce a series of serious diseases. Practice has proved that traditional Chinese medicine treatment has significant efficacy for sudden and refractory respiratory diseases. It is of great significance to develop new therapeutic drugs with clear targets from traditional Chinese medicine resources based on modern traditional Chinese medicine theory.

[0003] The use of Bletilla striata as medicine was first recorded in Shennong's Herbal Classic: it tastes bitter, sweet, astringent, and is neutral and cool in nature. It enters the lung, stomach, and liver meridians. It has the effects of tonifying the lung, stopping bleeding, reducing swelling, promoting tissue regeneration, and healing sores. Yifang Jijie records that grinding Bletilla striata into powder and taking it with rice drink can cure cough, pulmonary tuberculosis, and hemoptysis. In the early stage, the material basis of the Yifei Tongluo prescription through inflammatory immunity and in vivo pharmacokinetics have been evaluated. When evaluating its decomposition, it was found that the small molecule component of the main drug Bletilla striata has a significant anti-inflammatory effect, can inhibit the expression of NF-κB, effectively improve acute lung injury, and prevent the occurrence of fibrosis after injury.

[0004] Currently, there is no record or report in the prior art about the application of Phochinenin I in the preparation of drugs for preventing inflammation-induced diseases, nor is there any relevant technical inspiration. Summary of the invention

[0005] The technical problem to be solved by the present invention is to provide the use of Phochinenin I in the preparation of drugs for preventing inflammation-induced diseases. The drug has the potential to become a lead drug for treating inflammation and is expected to be used in the preparation of drugs for preventing and treating pulmonary inflammatory diseases, chronic obstructive pulmonary diseases, autoimmune diseases, atherosclerotic diseases or tumor diseases.

[0006] The present invention adopts the following technical solutions to achieve the invention objectives:

[0007] The use of Phochinenin I in the preparation of a drug for preventing inflammation-induced diseases is characterized by:

[0008] The chemical structure of Phochinenin I is:

[0009]

[0010] The present invention has found through research that Phochinenin I can inhibit the phosphorylation increase of STAT3 induced by LPS and IFN-γ in RAW264.7 mouse macrophages, reduce the production of inflammatory factors IL-6 and TNF-α; and reduce the production of iNOS, reduce NO secretion and thus downregulate the cellular inflammatory response. Therefore, Phochinenin I has the potential to be developed into a pathway for inhibiting inflammation with STAT3 and iNOS as targets.

[0011] As a further limitation of the present technical solution, the inflammation-induced disease is a lung inflammatory disease, chronic obstructive pulmonary disease, an autoimmune disease, an atherosclerotic disease or a tumor disease.

[0012] As a further limitation of the technical solution, the application of regulating the phosphorylation of STAT3 and reducing the production of iNOS and NO.

[0013] Compared with the prior art, the advantages and positive effects of the present invention are:

[0014] The present invention provides the anti-inflammatory activity of Phochinenin I and specifically provides the anti-inflammatory mechanism of the compound, laying a foundation for the preparation of the compound into a corresponding drug. Phochinenin I inhibits lung inflammation by regulating the phosphorylation of STAT3 and reducing the production of downstream iNOS. It has the potential to become a lead drug for the treatment of inflammation and is expected to be used in the preparation of drugs for the prevention and treatment of lung inflammation, chronic obstructive pulmonary disease, autoimmune diseases, atherosclerotic diseases or tumor diseases. BRIEF DESCRIPTION OF THE DRAWINGS

[0015] Figure 1 The figure is a schematic diagram showing that Phochinenin I of the present invention reduces the increase of inflammatory factors TNF-α and IL-6 in the supernatant of RAW264.7 cells induced by LPS and IFN-γ, and reduces the concentration of intracellular ROS.

[0016] Figure 2 The figure is a schematic diagram showing that Phochinenin I of the present invention inhibits LPS-induced NO production and iNOS expression in RAW264.7 cells.

[0017] Figure 3 The immunoblot analysis diagram of Phochinenin I of the present invention shows that Phochinenin I regulates the phosphorylation of STAT3 and the expression of c-myc, and can significantly increase the expression of Nrf-2. DETAILED DESCRIPTION

[0018] A specific implementation of the present invention is described in detail below in conjunction with the accompanying drawings, but it should be understood that the protection scope of the present invention is not limited by the specific implementation.

[0019] The chemical structure of Phochinenin I of the present invention is:

[0020]

[0021] The Phochinenin I is commercially available. During the specific implementation of the present invention, the Phochinenin I is purchased from TargetMol Company with the product number: TN5739.

[0022] The present invention found that Phochinenin I can inhibit the increase of STAT3 phosphorylation induced by LPS and IFN-γ in RAW264.7 mouse macrophages, reduce the production of inflammatory factors IL-6 and TNF-α; at the same time, it inhibits the production of iNOS, reduces NO secretion and thus downregulates the cellular inflammatory response. Therefore, Phochinenin I has the potential to be developed into a pathway that targets STAT3 and iNOS to inhibit inflammation.

[0023] The invention provides a drug for inhibiting STAT3 phosphorylation and iNOS inflammatory pathway. The drug comprises Phochinenin I and a pharmaceutically tolerable carrier.

[0024] The present invention provides the use of Phochinenin I in drugs for preventing inflammation-induced diseases; the inflammatory diseases preferably include pulmonary inflammatory diseases, chronic obstructive pulmonary diseases, autoimmune diseases, atherosclerotic diseases or tumor diseases, but are not limited to the above diseases.

[0025] The present invention provides the application of Phochinenin I in drugs for preventing inflammation-induced diseases, which can regulate the phosphorylation of STAT3 and reduce the generation of iNOS and NO.

[0026] The technical solutions in the present invention will be described clearly and completely below in conjunction with the embodiments of the present invention. Obviously, the described embodiments are only a part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0027] The effect of Phochinenin I on inflammatory mediators was evaluated using mouse macrophage RAW264.7 cells. The results showed that Phochinenin I could inhibit the increase of IL-6 and TNF-α induced by LPS and INF-γ at a non-toxic dose, indicating that Phochinenin I has the effect of inhibiting inflammatory mediators ( Figure 1 ).

[0028] Mouse macrophage RAW264.7 cells were used to evaluate the effect of Phochinenin I on intracellular ROS. The results of fluorescent probe DCFH-DA staining showed that Phochinenin I could reduce the generation of ROS caused by LPS and INF-γ in cells, that is, Phochinenin I has the effect of reducing cellular oxidative stress ( Figure 1 ).

[0029] Mouse macrophages RAW264.7 were used to evaluate the effect of Phochinenin I on iNOS and NO release. Western blot analysis and PCR results showed that Phochinenin I could attenuate LPS-induced NO production and iNOS expression in RAW264.7 cells ( Figure 2 );

[0030] The effects of Phochinenin I on the STAT3 signaling axis and iNOS were evaluated using mouse macrophage RAW264.7 cells. Western blot analysis showed that Phochinenin ed(I) could reduce the phosphorylation level of STAT3 and the expression of c-myc, and upregulate the protein level of the inflammation-related protein Nrf-2 ( Figure 3 ).

[0031] Preferably, in the above research situation, the concentration of Phochinenin I is 2.5-10 μM, which has a better protective effect on cells.

[0032] In order to enable those skilled in the art to more clearly understand the technical solution of the present application, the technical solution of the present application will be described in detail below in conjunction with specific embodiments.

[0033] Example 1: Phochinenin I inhibits the production of TNF-α and IL-6 in RAW264.7 cells induced by LPS and IFN-γ at non-toxic doses

[0034] (1) Culture of mouse macrophages RAW264.7

[0035] Mouse macrophage RAW264.7 was purchased from the American Type Culture Collection (ATCC), and cultured in a 37°C, 5% CO2 incubator using DMEM medium to which 10% fetal bovine serum (FBS) and 5% glutamine were added.

[0036] (2) Phochinenin I inhibits the expression of inflammatory factors co-induced by LPS and IFN-γ Method: Detection of inflammatory factor concentration by enzyme-linked immunosorbent assay

[0037] RAW264.7 cells were inoculated in a 24-well plate and cultured to a density of 70%-80%. RAW264.7 cells were stimulated with 1000ng / mL LPS and 20ng / mL IFN-γ for 4h, and then pre-protected with different concentrations of Phochinenin I for 6h. The cell culture medium was aspirated, centrifuged, and the supernatant was taken. The luminescence intensity was measured at 450nm according to the instructions of the enzyme-linked immunosorbent assay kit. The concentration of inflammatory factors was calculated based on the standard curve.

[0038] Results: The results of ELISA showed that ( Figure 1 ), Phochinenin I has the ability to inhibit the production of TNF-α and IL-6.

[0039] Example 2: Phochinenin I inhibits ROS production induced by LPS and IFN-γ

[0040] Methods: Immunofluorescence was used to detect the concentration of intracellular ROS

[0041] The cells were seeded in a 24-well plate, and RAW264.7 cells were inoculated. After the cells adhered to the wall, Phochinenin I was added for 6 hours, and then incubated with LPS and IFN-γ for 6 hours. 0.5 mL of 10 μM DCFH-DA solution was added. Incubate in a 37°C cell culture incubator for 20 minutes. Wash the cells three times with serum-free cell culture medium to fully remove the DCFH-DA that did not enter the cells. After collecting the cells, use a fluorescent microplate reader to detect, using an excitation wavelength of 488 nm and an emission wavelength of 525 nm.

[0042] Results: The results show ( Figure 1 B), Phochinenin I reduces the generation of intracellular ROS.

[0043] Example 3: Phochinenin I downregulates iNOS levels

[0044] Methods: Western blot analysis was used to detect changes in protein levels in cells

[0045] RAW264.7 cells were inoculated in 6-well plates and cultured until the density reached 70%-80%. The cells were stimulated with 1000ng / mL LPS and INF-γ for 6h, and then pre-protected with different concentrations of Phochinenin I for 12h. The cells were washed with PBS twice, and the cell lysis buffer was added. The protein was collected and the protein concentration was determined by Bradford method. Each sample protein (100μg) was loaded, and the protein components were separated by SDS-PAGE and the protein bands were transferred to nitrocellulose membranes by electrotransfer. The membranes were blocked with 5% skim milk powder solution prepared by TBS at room temperature for 1h, and then incubated with the antibodies of the proteins to be tested at 4℃ overnight. After washing with TBS, the secondary antibodies coupled with horseradish peroxidase were added and incubated for 1h, and the protein analysis was performed by enhanced ECL chemiluminescence.

[0046] Results: The results show ( Figure 2 A), After cells were treated with Phochinenin I, the increase in iNOS protein level was significantly inhibited.

[0047] Example 4: Phochinenin I inhibits LPS-induced NO production in RAW264.7 cells at a non-toxic dose

[0048] NO generation inhibition experiment: RAW264.7 cells were inoculated in 96-well plates and cultured to a density of 70%-80%. LPS (1 μg / mL) and iFN-γ were added for 6 hours. The cells were pretreated with different concentrations of the test compound for 12 hours. Subsequently, 100 μL of the culture supernatant was taken and mixed with an equal volume of Griess reagent (0.1% naphthylethylenediamine and 1% sulfonamide in 5% H3PO4 solution). After incubation at room temperature for 15 minutes, the absorbance was measured at 570 nm, and the NO content was evaluated by the NaNO2 standard curve.

[0049] Results: Figure 2 As shown in B, at 10 μM, Phochinenin I was able to inhibit LPS-induced NO production in RAW 264.7 macrophages.

[0050] Example 5: Phochinenin I inhibits the increase in iNOS mRNA level induced by LPS and IFN-γ Method: qRT-PCR method to detect iNOS mRNA level

[0051] RAW264.7 cells were seeded in six-well plates and cultured until the density reached 70%-80%. RAW264.7 cells were stimulated with 1000 ng / mL LPS and IFN-γ for 12 h, and pre-protected with different concentrations of Phochinenin I for 12 h. The mRNA content of iNOS was detected by qRT-PCR.

[0052] Results: qRT-PCR results showed ( Figure 2 C) Phochinenin I can block the increase in iNOS mRNA levels induced by LPS and IFN-γ.

[0053] Example 6: Phochinenin I downregulates STAT3 phosphorylation and c-myc levels and upregulates Nrf-2 expression

[0054] Methods: Western blot analysis was used to detect changes in protein levels in cells

[0055] RAW264.7 cells were seeded in 6-well plates and cultured until the density reached 70%-80%. The cells were stimulated with 1000 ng / mL LPS and INF-γ for 6 h, and then pre-protected with different concentrations of Phochinenin I for 6 h. The protein level was then detected by immunoblotting.

[0056] Results: The results show ( Figure 3 ), after cells were treated with Phochinenin I, the phosphorylation level of p-STAT3 and the increase of c-myc protein level were significantly inhibited, and the level of Nrf-2 protein was effectively increased.

[0057] The above disclosure is only a specific embodiment of the present invention, but the present invention is not limited thereto, and any changes that can be conceived by those skilled in the art should fall within the protection scope of the present invention.

Claims

1. Use of Phochinenin I in the preparation of a drug for preventing inflammation-induced diseases, characterized in that: The chemical structure of Phochinenin I is:

2. The use according to claim 1, characterized in that: The inflammation-induced disease is a lung inflammatory disease, chronic obstructive pulmonary disease, an autoimmune disease, an atherosclerotic disease or a tumor disease.

3. The use according to claim 2, characterized in that: It can regulate the phosphorylation of STAT3 and reduce the production of iNOS and NO.